Technology 90 of 266
Monoclonal antibodies
6 EIC Accelerator winners build on Monoclonal antibodies, 1% of the classified companies, in 1 sector and 2 industries.
6
Companies
1
Sectors
2
Industries
6
Countries
17%
Exits
33%
Show signs of scaling
Sectors
- Health6 (100%)
Industries
Used together with
Other technologies of the same companies
- Antibody-drug conjugates1
- Immunotherapy1
- Microfluidics1
- Protein engineering1
Companies per year of first award
2019
2020
2021
2022
2023
2024
- Monoclonal antibodies
Show the numbers
| Companies | Monoclonal antibodies | |
|---|---|---|
| 2019 | 1 | 1 |
| 2020 | 2 | 2 |
| 2021 | 2 | 2 |
| 2022 | 0 | 0 |
| 2023 | 1 | 1 |
| 2024 | 0 | 0 |
What happened to them (6 of 6 checked)
- Active4 (67%)
- Exit1 (17%)
- Failed1 (17%)
- Other0 (0%)
Signs of scaling
- Scaling2 (33%)
- Not scaling1 (17%)
- Scaling unclear3 (50%)
Keywords
- Antibody discovery
- B cells
- Canine antibodies
- Checkpoint inhibitors
- Clever-1
- Combination therapy
- Companion animals
- COVID-19
- Head and neck cancer
- Immuno-oncology
- Immunotherapy resistance
- Inflammatory bowel disease
- L1CAM
- Macrophages
- Myelodysplastic syndrome
- Oncology
- Out-licensing
- Ovarian cancer
- Pancreatic cancer
- Pet health
- Phage display
- Single-cell analysis
- Solid tumours
All 6 companies using Monoclonal antibodies
| Company | Project | Industry | Country | Cut-off | Funding | Status | Rasph |
|---|---|---|---|---|---|---|---|
| NECTIN THERAPEUTICS | NTX1088First-in-class anti-PVR mAb NTX1088 - a novel oncology drug that unlocks the power of human immune system and revolutionizes cancer care | Biopharmaceuticals | Israel | November 2023 | Grant first | Active | Deep dive |
| ADIVO GMBH | CAESAR IBD ProjectThe CAESAR IBD Project: Developing Therapeutic Antibodies for Pets | Animal health | Germany | October 2021 | Blended finance | Acquired | Deep dive |
| NETRIS PHARMA SAS | ImmunoNetInhibiting resistance to immunotherapy in Oncology by targeting Netrin-1 | Biopharmaceuticals | France | October 2021 | Blended finance | Active | Deep dive |
| Faron Pharmaceuticals Oy | MAGIFFaron leading the way in macrophage guided immunotherapy | Biopharmaceuticals | Finland | March 2020 | Grant only | Active | Deep dive |
| Remedy Biologics Limited | RapCo-19Rapid COVID-19 Passive Therapy Response Platform | Biopharmaceuticals | Ireland | March 2020 | Blended finance | Active | Deep dive |
| Elthera AG | Anti-L1CAMAnti-L1CAM antibody: A novel efficacious immunotherapy for pancreatic and ovarian cancer patients | Biopharmaceuticals | Switzerland | January 2019 | Grant only | Dormant | Deep dive |